Credit: Shutterstock

So much to say, so lit­tle space. FDA-led stud­ies as­sess risk in­for­ma­tion on so­cial me­dia

How should phar­ma com­pa­nies use the lim­it­ed char­ac­ter space in a pro­mo­tion­al tweet? While in­clud­ing risk in­for­ma­tion in the body of a post made pa­tients more like­ly to rec­og­nize po­ten­tial dan­gers, new FDA-led re­search sug­gests it al­so made them less like­ly to pur­sue more in­for­ma­tion.

The FDA said in draft guid­ance back in 2014 that if a com­pa­ny pro­motes a drug on so­cial me­dia, it should al­so in­clude the most se­ri­ous risks in the body of that post — re­gard­less of char­ac­ter-space lim­i­ta­tions (CSL). Reg­u­la­tors told drug­mak­ers to in­clude a link de­vot­ed sole­ly to the com­mu­ni­ca­tion of risks.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.